Twist Bioscience Corp (NASDAQ:TWST)
| Market Cap | 10.40B+424.2% |
| Revenue (ttm) | 431.80M+19.2% |
| Net Income | -136.72M-60.5% |
| EPS | -2.22-52.1% |
| Shares Out | 62.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,525,027 |
| Open | 209.55 |
| Previous Close | 205.00 |
| Day's Range | 164.56 - 219.71 |
| 52-Week Range | 23.30 - 219.71 |
| Beta | 2.22 |
| Analysts | Buy |
| Price Target | 131.33(-21.35%) |
| Earnings Date | Nov 13, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About TWST
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TWST stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TWST holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TWST's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TWST Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TWST Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| NGS applications | $61.80M | 52.21% |
| DNA synthesis and protein solutions | $56.57M | 47.79% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TWST patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TWST from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TWST
| ETF | Est. Holding Size |
|---|---|
| ARKKARK Innovation ETF | $417.61M |
| IWMiShares Russell 2000 ETF | $353.56M |
| VTIVanguard Morningstar Total Stock Market ETF | $276.54M |
| ARKGARK Genomic Revolution ETF | $246.74M |
| XBIState Street SPDR S&P Biotech ETF | $239.17M |
| VBVanguard Morningstar Small-Cap ETF | $200.04M |
Estimated from each fund’s disclosed top holdings × AUM
TWST Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TWST’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score